Bird – Talk Bio

Aviceda’s AVD-104 misses Phase 2b primary endpoint vs Izervay but still headed to Phase 3

2 months ago talkbio0Tagged avacincaptad, AVD-104, Clinical trial failure, Clinical Trials, Dry AMD, Genus Aviceda, Geographic Atrophy, IZERVAY, pegol, Phase 3 prospects, Sialic Acid Binding Immunoglobulin-like Lectins

Aviceda; AVD-104; geographic atrophy; dry AMD; Phase 2b; SIGLEC trial; Izervay; avacincaptad pegol; clinical trial failure; Phase 3 prospects

Endpoints 11: Biopharma’s most promising startups revealed live in Boston this September

6 months ago talkbio0Tagged Aves, Biopharma, biotech startups, biotechs, Boston event, Endpoints, GALA peptide, Industry, Rating (action), real-time, State Room

Endpoints 11; biotech startups; biopharma; Boston event; State Room; awards gala; early bird rate; industry insiders; 2025 most promising biotechs; real-time reveal

Royalty Market Accelerates with XOMA Biotech Acquisitions and OrbiMed’s Major Fundraise

6 months ago talkbio0Tagged Arenaria, Biological Factors, Biological Science Disciplines, biopharma financing, Conditional, HilleVax, Investments, LAVA, M&A, mezigitamab, OrbiMed, royalty acquisition, XOMA Royalty

royalty acquisition; XOMA Royalty; biotech M&A; OrbiMed; biopharma financing; mezigitamab; Turnstone Biologics; HilleVax; LAVA Therapeutics; contingent value rights; life sciences investment

Trump Administration Unveils Health Data Sharing Scheme Backed by Apple, Amazon, and Others

6 months ago talkbio0Tagged Administration occupational activities, Amazona, CMS Interoperability Framework, digital health records, Genus Malus, health data, Privacy, tech partnerships, Transplant Registry Unified Management Program

Trump administration; health data sharing; CMS Interoperability Framework; Apple; Amazon; digital health records; patient data; privacy; tech partnerships

Merck Terminates Midstage Asset from $1.9B Pandion Acquisition over Lack of Clinical Benefit

6 months ago talkbio0Tagged asset termination, Benefit, biotech acquisition, Clinical Trials, lack of, Merck, Pandion

Merck; Pandion Therapeutics; asset termination; clinical trial; lack of benefit; biotech acquisition

Bluebird Private Equity Buyout Boosts Upfront Cash for Shareholders

9 months ago talkbio0Tagged Capital, Carlyle, contingent value right, CVR, DKK1 gene, Family Turdidae (organism), Merger, Private Equity, shareholders, upfront cash

Bluebird; private equity buyout; shareholders; upfront cash; Carlyle; SK Capital; contingent value right; CVR; buyout terms; merger

Generation Gold Standard: HHS’s $500 Million Initiative for Universal Vaccine Development

9 months ago talkbio0Tagged Bhattacharya, BPL, Genus: Coronavirus, Jay, NIH Mouse, pandemic preparedness, propiolactone, Universal, Vaccines, whole-virus

Universal vaccines, beta-propiolactone (BPL), whole-virus platform, influenza, coronavirus, NIH, Jay Bhattacharya, Robert F. Kennedy Jr., pandemic preparedness

Novartis bolsters renal disease pipeline with $1.7B deal for Regulus

9 months ago talkbio0Tagged farabursen, Goldcrest, Novartis

Goldcrest, farabursen, Novartis

Novartis to buy Regulus Therapeutics for up to $1.7B

9 months ago talkbio0Tagged Acquisition (action), Goldcrest, Kidney Diseases, Novartis

Goldcrest, Novartis, Acquisition (action), Kidney Diseases

Ayrmid misses deadline for detailed offer to top private equity bid for bluebird

10 months ago talkbio0Tagged Ayrmid, Capital, deadline, Failed, Family Turdidae (organism), gene therapy, Private Equity, proposal - intent, United States Food and Drug Administration

Ayrmid, Family Turdidae (organism), gene therapy, Failed, Capital, proposal – intent, United States Food and Drug Administration, private equity, deadline